Multiepitope Peptide Vaccination in Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00153569
Recruitment Status : Unknown
Verified September 2005 by Charite University, Berlin, Germany.
Recruitment status was:  Active, not recruiting
First Posted : September 12, 2005
Last Update Posted : May 26, 2010
Information provided by:
Charite University, Berlin, Germany

Brief Summary:
This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Biological: Tyrosinase, MAGE-3, GnTV Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma
Study Start Date : March 2003
Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Primary Outcome Measures :
  1. Clinical efficacy

Secondary Outcome Measures :
  1. Immune response
  2. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic melanoma
  • HLA-A1, -A2, -A24, -B44

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00153569

Hem&Onc Charité CBF
Berlin, Germany, 12200
Sponsors and Collaborators
Charite University, Berlin, Germany
Principal Investigator: Ulrich Keilholz, MD Charité, CBF

Publications: Identifier: NCT00153569     History of Changes
Other Study ID Numbers: HaemaCBFMM03
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: May 26, 2010
Last Verified: September 2005

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas